Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices

被引：185

作者：

Niespodziany, I ^{[1
]}

Klitgaard, H ^{[1
]}

Margineanu, DG ^{[1
]}

机构：

[1] UCB SA, Pharma Sector, Res & Dev, Preclin CNS Res, B-1420 Braine Alleud, Belgium

来源：

NEUROSCIENCE LETTERS | 2001年 / 306卷 / 1-2期

关键词：

levetiracetam; high-voltage-activated Ca2+ current; epilepsy; CA1 pyramidal neurones; hippocampal slice;

D O I：

10.1016/S0304-3940(01)01884-5

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The effect of the new antiepileptic drug levetiracetam (LEV; KEPPRA(TM)) on the neuronal high-voltage-activated (HVA) Ca2+ current was investigated on pyramidal neurones, visually identified in the CA1 area of rat hippocampal slices. Nystatin-perforated patch clamp recordings were made under experimental conditions designed to study HVA Ca2+ currents. The HVA current, activated by steadily increasing voltage-ramps, was reversibly eliminated by Cd2+ and depressed by either nimodipine, or omega -Conotoxin GVIA. After 30 min perfusion of the slices with LEV 32 muM, the current decayed to 55 +/- 9% (mean +/- SEM; n = 9) of the initial value, which is significantly (P < 0.05, two-tailed t-test) lower than the rundown to 84 +/- 10% in a control group (n = 10) of neurones. The limited, but significant depression of the neuronal HVA Ca2+ current, produced by LEV at a clinically relevant concentration, might contribute to the antiepileptic action of the drug. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：5 / 8

页数：4

共 20 条

[1] Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists [J].

Ambrósio, AF ;

Silva, AP ;

Malva, JO ;

Soares-da-Silva, P ;

Carvalho, AP ;

Carvalho, CM .

NEUROPHARMACOLOGY, 1999, 38 (09) :1349-1359

[2] Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission [J].

Birnstiel, S ;

Wulfert, E ;

Beck, SG .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (05) :611-618

[3] Levetiracetam for partial seizures - Results of a double-blind, randomized clinical trial [J].

Cereghino, JJ ;

Biton, V ;

Abou-Khalil, B ;

Dreifuss, F ;

Gauer, LJ ;

Leppik, I .

NEUROLOGY, 2000, 55 (02) :236-242

[4] Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy [J].

Klitgaard, H ;

Matagne, A ;

Gobert, J ;

Wülfert, E .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) :191-206

[5] Development of HVA and LVA calcium currents in pyramidal CA1 neurons in the hippocampus of the rat [J].

Kortekaas, P ;

Wadman, WJ .

DEVELOPMENTAL BRAIN RESEARCH, 1997, 101 (1-2) :139-147

[6]

Löscher W, 1998, J PHARMACOL EXP THER, V284, P474

[7] PROFILE OF UCB-L059, A NOVEL ANTICONVULSANT DRUG, IN MODELS OF PARTIAL AND GENERALIZED EPILEPSY IN MICE AND RATS [J].

LOSCHER, W ;

HONACK, D .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 232 (2-3) :147-158

[8]

Margineanu DG, 2000, PHARMACOL RES, V42, P281

[9] Inhibition by levetiracetam of a non-GABA(A) receptor-associated epileptiform effect of bicuculline in rat hippocampus [J].

Margineanu, DG ;

Wulfert, E .

BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (06) :1146-1150

[10]

Niespodziany I, 2000, NEUROLOGY, V54, pA307

← 1 2 →